Strides Pharma Science Limited has announced a significant milestone with USFDA approval for acetaminophen and ibuprofen tablets, 125 mg/250 mg. This development is set to enhance the company’s over-the-counter (OTC) product offerings in the pain relief segment.
Key Highlights:
- Product Approved: Acetaminophen and Ibuprofen Tablets (125 mg/250 mg).
- Purpose: Provides dual-action pain relief for conditions such as headaches, muscle aches, menstrual cramps, and arthritis.
- Equivalent Product: Bioequivalent to Advil Dual Action with Acetaminophen by Haleon US Holdings LLC.
- Manufacturing Facility: To be produced at the company’s flagship Bengaluru facility.
About Strides:
Headquartered in Bengaluru, India, Strides Pharma Science Limited operates in regulated markets and focuses on challenging-to-manufacture products sold in over 100 countries. The company has global manufacturing facilities in India, Italy, Kenya, and the United States.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Always consult relevant professionals before making business or investment decisions.
TOPICS:
Strides Pharma